Early detection Leverage Nucleix’s CE-marked Bladder EpiCheck and FDA-cleared bladder cancer recurrence test to target urology clinics, cancer centers, and health systems prioritizing non-invasive, early detection strategies to reduce treatment costs and improve outcomes.

Clinical collaboration Position partnerships with leading cancer centers (e.g., MD Anderson) to co-develop biomarkers and validate in subtypes like SCLC, creating joint offerings and accelerating adoption through academic and translational research channels.

Expansion opportunities Capitalize on their US and Israel dual footprint and a growing North American presence to approach hospital networks, IDNs, and regional health systems with scalable EpiCheck workflows and physician-friendly testing options.

Commercial leadership Engage with Nucleix leadership moves and recent C-suite hires to align value propositions with commercial strategy, emphasizing market education, payer discussions, and rapid sales cycles in oncology diagnostics.

Market readiness Target biopharma and CROs involved in oncology trials and real-world evidence studies to integrate EpiCheck into trial endpoints and monitoring programs, expanding from diagnostic use to treatment guidance and recurrence surveillance.